Christopher Durant Turner - 06 Jan 2023 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Role
Chief Medical Officer
Signature
/s/ Deborah Ann Miller, attorney-in-fact
Issuer symbol
NUVL
Transactions as of
06 Jan 2023
Net transactions value
$0
Form type
4
Filing time
06 Jan 2023, 15:47:16 UTC
Previous filing
19 May 2022
Next filing
07 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUVL Stock Option (Right to Buy) Award $0 +144,200 $0.000000 144,200 06 Jan 2023 Class A Common Stock 144,200 $27.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest over the next four years in equal monthly installments following January 6, 2023, subject to continued service to Nuvalent, Inc. through the applicable vesting date.